| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
|
Lancet Oncol
|
2013
|
4.20
|
|
2
|
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.95
|
|
3
|
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
1.52
|
|
4
|
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
|
J Thorac Oncol
|
2011
|
1.43
|
|
5
|
Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
|
J Thorac Oncol
|
2009
|
1.03
|
|
6
|
Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population.
|
J Thorac Oncol
|
2010
|
0.92
|
|
7
|
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
|
Lung Cancer
|
2012
|
0.87
|
|
8
|
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
|
Asia Pac J Clin Oncol
|
2012
|
0.86
|
|
9
|
Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.
|
Lung Cancer
|
2010
|
0.85
|
|
10
|
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
|
J Thorac Oncol
|
2015
|
0.80
|
|
11
|
[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
|
Zhongguo Fei Ai Za Zhi
|
2012
|
0.77
|
|
12
|
[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2004
|
0.76
|
|
13
|
Functional roles of PC-PLC and Cdc20 in the cell cycle, proliferation, and apoptosis.
|
Cell Biochem Funct
|
2010
|
0.76
|
|
14
|
Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer.
|
Onco Targets Ther
|
2013
|
0.75
|
|
15
|
[Trend of molecular target therapy of non-small cell lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2004
|
0.75
|
|
16
|
[Guideline for diagnosis and treatment of ALK positive non-small cell lung cancer in China].
|
Zhonghua Bing Li Xue Za Zhi
|
2015
|
0.75
|
|
17
|
[Guideline of surgical practice for non-small cell lung cancer based staging].
|
Zhongguo Fei Ai Za Zhi
|
2004
|
0.75
|
|
18
|
[Decline of dendritic cells in the peripheral blood of patients with non-small cell lung cancer and its relation to vascular endothelial growth factor].
|
Zhongguo Fei Ai Za Zhi
|
2002
|
0.75
|
|
19
|
[Practice guidelines in diagnosis and staging of lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2003
|
0.75
|
|
20
|
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
|
Lancet Oncol
|
2009
|
0.75
|
|
21
|
[A primary study of immunotherapy with carcinoembryonic antigen peptide-pulsed, autologous human cultured dendritic cells in patients with advanced non-small cell lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2006
|
0.75
|
|
22
|
[The role of surgery and multimodality therapy in the treatment of early-stage lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2003
|
0.75
|
|
23
|
[Advances in multimodality therapy of lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2003
|
0.75
|
|
24
|
[The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer].
|
Zhonghua Jie He He Hu Xi Za Zhi
|
2002
|
0.75
|
|
25
|
[Value of cardiopulmonary risk index in predicting postoperative short-term prognosis in patients with lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2002
|
0.75
|